Taro Pharmaceutical Industries Ltd. said Friday the Food and Drug Administration approved its Topicort spray as a treatment for plaque psoriasis.

The company said Topicort, or desoximetasone, is approved for patients age 18 and older. Taro said U.S. consumers spend about $100 million per year on corticosteroid sprays.

Taro shares gained a penny to $57.98 Friday.